Reliability of pressure pain threshold to discriminate individuals with neck and low back pain.

BACKGROUND: Pressure pain threshold (PPT) is decreased in several musculoskeletal disorders, giving indirect evidence regarding pain status. Despite the fact that PPT has been already proven to be reliable in patients with acute conditions, there is great variability of methods and results observed within studies, and only a few evidences confirming its reliability in chronic conditions. OBJECTIVE: The objective of this study was to determine the test-retest reliability of PPT in the neck and low back regions to discriminate individuals with neck or low back pain from healthy individuals. Additionally, one secondary aim was to establish the minimum detectable change (MDC) and the standard error of measurement for future clinical studies and interventions. METHODS: In this reliability study, 74 individuals (15 individuals from the neck pain and 17 from the neck control group; 21 individuals from the low back pain and 21 from the low back control group). PPT was measured in the neck region (suboccipital, trapezius and supraspinal muscles) and in the lower back region (paraspinal muscles in the levels of L1, L3 and L5). Intrarater reliability was assessed using intraclass correlation coeficient and Bland-Altman. RESULTS: Excellent intra-rater reliability was observed for both (ICC of 0.874 for the neck pain versus ICC of 0.895 in neck control group; ICC of 0.932 for the low back pain group versus ICC of 0.839 for the control group). A small bias was observed for all groups (-0.08 for the neck pain group versus 0.10 in the control group; and 0.32 in low back pain group versus 0.44 in the control group). Minimum detectable change of 0.63 kgf of neck pain and 1.21 kgf of low back pain was calculated. It was found difference in PPT between pain and control groups (p< 0.05). CONCLUSION: It may be suggested that the protocol with PPT is reliable and able to discriminate individuals with and without neck and low back pain with a minor measurement error. Therefore, this method may be used to detect possible progress after interventions in patients with neck or low back pain.

Association of interleukin-6 gene polymorphism (rs1800796) with severity and functional status of osteoarthritis in elderly individuals.

Osteoarthritis (OA) is the most prevalent disease of the musculoskeletal system and it has an important genetic component. Despite several reports have shown the involvement of pro-inflammatory cytokine such as interleukin-1ß and TNF-α, the role of interleukin-6 (IL-6) in osteoarthritis is still unclear. Thus, this study aimed to analyze the relationship between the single nucleotide polymorphism in the portion -572 of the promoter region of the IL6 gene (SNP -572G/C) with hip and knee OA in the elderly. In this case-control study, 257 physically independent elderly were recruited (case group: 92 individuals with osteoarthritis and control group: 165 individuals with no osteoarthritis). Blood samples were collected from patients for the DNA fragments extraction and amplification by real-time polymerase chain reaction (PCR) by TaqMan system for subsequent genotyping of IL6 gene. The degree of joint damage was assessed by radiographic classification based on the criteria of Kellgren and Lawrence. The functional status was evaluated by Lequesne and WOMAC questionnaires. It was observed that individuals carrying the C allele have lower susceptibility to osteoarthritis (OR=0.51, 95% CI: 0.32-0.80, p=0.004) and less radiological impairment for both hip (Fisher-Freeman-Halton test=4.2 and p=0.04) and knee joints (Fisher-Freeman-Halton test=4.7 and p=0.03). Regarding functional status, individuals carrying the C allele has a lower degree of functional impairment assessed by WOMAC (Mann-Whitney test, p=0.04), although no difference was observed in the Lequesne questionnaire (p>0.05). Additionally, it was observed a marked reduction in IL-6 serum levels in individuals with GC and CC genotypes when compared to individuals harboring GG genotype. In conclusion, the polymorphism -572G/C IL6 is a protective factor for the presence and severity of hip and knee osteoarthritis in the elderly. Further prospective studies with large sample size and methods (e.g. effect of this polymorphism on gene expression, haplotype analysis for IL-6 promoter polymorphism) are needed to validate this study findings.

Análise da funcionalidade de idosos com osteoartrite / Análisis de la funcionalidad de ancianos con osteoartritis / Analysis of functional status of elderly with osteoarthritis

O objetivo deste estudo foi analisar a influência do gênero, idade e farmacoterapia da osteoartrite (OA) sobre a funcionalidade de idosos. Trata-se de um estudo transversal com 105 idosos de ambos os gêneros (Idade: 70,73±6,0 anos) e portadores de OA de quadril e/ou joelho, confirmado por análise radiográfica. A funcionalidade foi avaliada por dois instrumentos: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) e Índice Algofuncional de Lequesne. As análises dos dados apresentaram pior funcionalidade tanto no questionário Lequesne (p=0,007) como no WOMAC (p=0,013) e em seus domínios Intensidade da Dor (p=0,013), Rigidez (p=0,032) e Funcionalidade (p=0,018). Contudo, não foram verificadas diferenças nos instrumentos avaliados quanto a diferentes faixas etárias ou comprometimento da articulação segundo alterações radiográficas (p>0,05). Foi observado que os medicados apresentavam pior funcionalidade em comparação aos que não utilizavam medicamentos para OA (Lequesne: p=0,005; WOMAC: p=0,008 e domínios: Intensidade da Dor: p=0,004; Rigidez: p=0,007 e Funcionalidade: p=0,023). No modelo multivariado, foi observado que o gênero e o tratamento farmacológico influenciam a funcionalidade de idosos portadores de OA (p<0,05), sendo as mulheres e os indivíduos medicados os que apresentam pior funcionalidade tanto no índice Lequesne quanto WOMAC. Observou-se pior funcionalidade em idosas portadoras de OA e que o uso de medicamentos para osteoartrite não promoveu melhora na condição funcional desses indivíduos.

En este estudio se analiza la influencia del género, de la edad y del tratamiento farmacológico para la osteoartritis (OA) en la funcionalidad de las personas mayores. Se trata de un estudio transversal, lo cual 105 personas mayores han participado de ambos géneros (Edad: 70,73±6,0 años) con OA de cadera y/o rodilla confirmado por el análisis radiográfico. Se valoró la funcionalidad bajo dos instrumentos: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) e Índice Algofuncional de Lequesne. En el análisis de datos se mostró peor funcionalidad tanto en el cuestionario Lequesne (p=0,007) como en el WOMAC (p=0,013) y en sus dominios intensidad de dolor (p=0,013), rigidez (p=0,032) y funcionalidad (p=0,018). No obstante, no se comprobaron diferencias en estos instrumentos en relación a las distintas franjas etarias o a la alteración de la articulación, de acuerdo a los indicios en la radiografía (p>0,05). Se observó que los que fueron tratados con medicamentos para la OA presentaban funcionalidad peor que los que no lo utilizaban (Lequesne, p=0,005; WOMAC, p=0,008; y dominios: intensidad de dolor, p=0,004; rigidez, p=0,007 y funcionalidad p=0,023). En el modelo multivariante, se observó que el género y el tratamiento farmacológico influyeron en la funcionalidad de las personas mayores con OA (p<0,05), siendo las mujeres y los sujetos tratados con medicamentos los que más presentaron peor funcionalidad tanto en el índice Lequesne como en el WOMAC, lo que muestra que el uso de medicamentos no mejoraron la condición funcional de estos.

The objective of this study was to analyze the influence of gender, age and pharmacological treatment for osteoarthritis (OA) on the functional status of physically independent elderly. This cross-sectional study involved 105 elder individuals from both genders (age: 68.80±6.3 years) with OA of the hip and / or knee, which was confirmed by radiographic analysis. Two specific instruments assessed functional status: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Lequesne Index. It was observed worse condition in females in Lequesne (p=0.007), global WOMAC (p=0.013), as well as in its fields: pain intensity (p=0.023), stiffness (p=0.032) and functional status (p=0.018). However, considering age and radiological status, no differences were observed between groups in all variables (p>0.05). It was observed that the individuals with pharmacological treatment for OA have poor functional status in all functional questionnaires (Lequesne, p=0.005; global WOMAC, p=0.008 as well as in specific WOMAC fields, such as Pain intensity, p=0.004; Stifness, p=0.007; and Functional status p=0.023). At multivariate modelo (multiple linear regression), it was observed that gender and pharmacological treatment may influence the functional status of elderly with OA, whereas women and medicated individuals are those showing the worse condition both in Lequesne and WOMAC indexes. It was observed worse functional status in women with osteoarthritis and pharmacological treatment evoked no improvement in functional status of these individuals.

[Analysis of the influence of pharmacotherapy on the quality of life of seniors with osteoarthritis]. / Análise da influência da farmacoterapia sobre a qualidade de vida em idosos com osteoartrite.

AIMS: This study aimed to assess the influence of pharmacotherapy on health-related quality of life of elderly with ostheoartritis. METHODS: Longitudinal study involving 91 older adults from both genders (Age: 70.36±5.57 years) from EELO project with self-reported knee or hip ostheoartritis, confirmed by radiographic analysis. Data regarding pharmacotherapy was assessed by a structured questionnaire and the quality of life was analyzed by SF-36 questionnaire at the initial moment and two years thereafter. All domains from quality of life were grouped in physical and mental components for further data analysis. RESULTS: A statistically significant decline in health-related quality of life was observed (Wilcoxon test, p<0.05). However, it was observed a slighted decline in physical components in group treated with chondroitin/glucosamine when compared to other groups, according to Kruskal-Wallis test (p=0.007). On the other hand, it was not observed any influence of pharmacological treatment on mental components of health-related quality of life (p>0.05). CONCLUSIONS: Treatment with condroitin/glucosamin contributes to a lower decline in physical component while it had no influence on mental component of health-related quality of life in older adults with ostheoartritis.